Antiretroviral therapy: A promising HIV prevention strategy?

Journal of Acquired Immune Deficiency Syndromes

Volumn 55, Issue SUPPL. 2, 2010, Pages

  El Sadr, Wafaa M ^a,b,c   Affrunti, Megan ^a   Gamble, Theresa ^d   Zerbe, Allison ^a  

^a Mailman School of Public Health   (United States)

^b Department of Neurology and the Taub Institute for Research on Alzheimer's Disease and the Aging Brain   (United States)

^c HARLEM HOSPITAL CENTER   (United States)

^d FAMILY HEALTH INTERNATIONAL   (United States)

Author keywords

Antiretroviral therapy; HIV treatment; Prevention; Transmission

Indexed keywords

ANTIRETROVIRUS AGENT;

ANTIVIRAL THERAPY; AWARENESS; BEHAVIOR CHANGE; CD4 LYMPHOCYTE COUNT; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION PREVENTION; MALE HOMOSEXUAL; MORBIDITY; PATIENT COMPLIANCE; PRIORITY JOURNAL; REVIEW; SURVIVAL TIME; UNITED STATES; VIRUS TRANSMISSION;

ANTI-HIV AGENTS; HIV INFECTIONS; HUMANS; PATIENT COMPLIANCE; POPULATION SURVEILLANCE; RISK FACTORS; SEXUAL BEHAVIOR; SOCIOECONOMIC FACTORS; SUBSTANCE-RELATED DISORDERS; UNITED STATES;

EID: 78649376054     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/QAI.0b013e3181fbca6e     Document Type: Review

References (62)

1. Garnett GP, Baggaley RF. Treating our way out of the HIV pandemic: could we, would we, should we? Lancet. 2009;373:9-11. doi:10.1016/S0140-6736 (08) 61698-0.
2. Granich RM, Gilks CF, Dye C, et al. Universal voluntary HIV testing with immediate antiretroviral therapy as a strategy for elimination of HIV transmission: a mathematical model. Lancet. 2009;373:48-57. doi: 10.1016/S0140-6736 (08) 61697-9.
3. Cohen MS, Mastro TD, Cates W Jr. Universal voluntary HIV testing and immediate antiretroviral therapy [correspondence; authors' reply, 1080-1081]. Lancet. 2009;373:1077-1081. doi:10.1016/S0140-6736 (09) 60640-1, doi:10.1016/S0140-6736 (09) 60648-6.
4. Dieffenbach CW, Fauci AS. Universal voluntary testing and treatment for prevention of HIV transmission. JAMA. 2009;301:2380-2382. doi: 10.1001/jama.2009.828.
5. Assefa Y, Lera M. Universal voluntary HIV testing and immediate antiretroviral therapy. Lancet. 2009;373:1080-1081. doi:10.1016/S0140-6736 (09) 60647-4.
6. Cu-Uvin S, Snyder B, Harwell JI, et al. Association between paired plasma and cervicovaginal lavage fluid HIV-1 RNA levels during 36 months. J Acquir Immune Defic Syndr. 2006;42:584-587. doi: 10.1097/01.qai.0000229997.52246.95.
7. Cohen MS, Hoffman IF, Royce RA, et al. Reduction of concentration of HIV-1 in semen after treatment of urethritis: implications for prevention of sexual transmission of HIV-1. AIDSCAP Malawi Research Group. Lancet. 1997;349:1868-1873. doi:10.1016/S0140-6736 (97) 02190-9.
8. Quinn TC, Wawer MJ, Sewankambo N, et al. Viral load and heterosexual transmission of human immunodeficiency virus type 1. Rakai Project Study Group. N Engl J Med. 2000;342:921-929.
9. Fiore JR, Suligoi B, Saracino A, et al. Correlates of HIV-1 shedding in cervicovaginal secretions and effects of antiretroviral therapies. AIDS. 2003;17:2169-2176. doi:10.1097/01.aids.0000088178.01779.b4.
10. Nagot N, Ouedraogo A, Weiss HA, et al. Longitudinal effect following initiation of highly active antiretroviral therapy on plasma and cervicovaginal HIV-1 RNA among women in Burkina Faso. Sex Transm Infect. 2008;84:167-170. doi:10.1136/sti.2007.027987.
11. Xu C, Politch JA, Tucker L, et al. Factors associated with increased levels of human immunodeficiency virus type 1 DNA in semen. J Infect Dis. 1997;176:941-947. Available at: http://www.journals.uchicago.edu/doi/pdf/10. 1086/516539. Accessed August 15, 2010.
12. Al-Harthi L, Kovacs A, Coombs RW, et al. A menstrual cycle pattern for cytokine levels exists in HIV-positive women: implication for HIV vaginal and plasma shedding. AIDS. 2001;15:1535-1543. Available at: http://journals.lww.com/ aidsonline/Fulltext/2001/08170/A-menstrual-cycle-pattern-for-cytokine-levels.11. aspx. Accessed August 15, 2010.
13. Velasco-Hernandez JX, Gershengorn HB, Blower SM. Could widespread use of combination antiretroviral therapy eradicate HIV epidemics? Lancet Infect Dis. 2002;2:487-493. doi:10.1016/S1473-3099 (02) 00346-8.
14. Wagner BG, Kahn JS, Blower S. Should we try to eliminate HIV epidemics by using a 'Test and Treat' strategy? AIDS. 2010;24:775-776. doi:10.1097/QAD. 0b013e3283366782.
15. Dodd PJ, Garnett GP, Hallett TB. Examining the promise of HIV elimination by 'test and treat' in hyperendemic settings. AIDS. 2010;24:729-735. doi:10.1097/QAD.0b013e32833433fe.
16. Walensky RP, Paltiel AD, Losina E, et al. Test and treat DC: forecasting the impact of a comprehensive HIV strategy in Washington DC. Clin Infect Dis. 2010;51:392-400. doi:10.1086/655130.
17. Bunnell R, Ekwaru JP, Solberg P, et al. Changes in sexual behavior and risk of HIV transmission after antiretroviral therapy and prevention interventions in rural Uganda. AIDS. 2006;20:85-92. Available at: http://journals.lww.com/aidsonline/Fulltext/2006/01020/Changes-in-sexual- behavior-and-risk-of-HIV12.aspx. Accessed August 15, 2010.
18. Donnell D, Baeten JM, Kiarie J, et al. Heterosexual HIV-1 transmission after initiation of antiretroviral therapy: a prospective cohort analysis. Lancet. 2010;375:2092-2098. doi:10.1016/S0140-6736 (10) 60705-2.
19. Wang L, Ge Z, Luo J, et al. HIV transmission risk among serodiscordant couples: a retrospective study of former plasma donors in Henan, China. JAcquir Immune Defic Syndr. 2010;55:232-238. Published online ahead of print, post author corrections, July 26, 2010.
20. Das M, Chu PL, Santos GM, et al. Decreases in community viral load are accompanied by reductions in new HIV infections in San Francisco. PLoS One. 2010;5(6): e11068. doi:10.1371/journal.pone.0011068.
21. Montaner JS, Lima VD, Barrios R, et al. Association of highly active antiretroviral therapy coverage, population viral load, and yearly new HIV diagnoses in British Columbia, Canada: a population-based study. Lancet. 2010;376:532-539.
22. Fang CT, Hsu HM, Twu SJ, et al. Decreased HIV transmission after a policy of providing free access to highly active antiretroviral therapy in Taiwan. J Infect Dis. 2004;190:879-885. doi:10.1086/422601.
23. Cohen MS, Gay CL. Treatment to prevent transmission of HIV-1. Clin Infect Dis. 2010;50(Suppl 3): S85-S95. doi:10.1086/651478.
24. Hall HI, Song R, Rhodes P, et al. Estimation of HIV incidence in the United States. JAMA. 2008;300:520-529. PMCID:PMC2919237.
25. Campsmith ML, Rhodes PH, Hall HI, et al. Undiagnosed HIV prevalence among adults and adolescents in the United States at the end of 2006. JAcquir Immune Defic Syndr. 2010;53:619-624.
26. Erratum in: J Acquir Immune Defic Syndr. 2010;54:112. doi:10.1097/QAI.0b013e3181bf1c45.
27. Marks G, Crepaz N, Janssen RS. Estimating sexual transmission of HIV from persons aware and unaware that they are infected with the virus in the USA. AIDS. 2006;20:1447-1450. doi:10.1097/01.aids.0000233579. 79714.8d.
28. MacKellar DA, Valleroy LA, Secura GM, et al. Unrecognized HIV infection, risk behaviors, and perceptions of risk among young men who have sex with men: opportunities for advancing HIV prevention in the third decade of HIV/AIDS. J Acquir Immune Defic Syndr. 2005;38:603-614.
29. El-Sadr WM, Mayer KH, Hodder SL. AIDS in America-forgotten but not gone. N Engl J Med. 2010;362:967-970. doi:10.1056/NEJMp1000069.
30. Department of Health, HIV/AIDS Administration. District of Columbia HIV/AIDS Epidemiology Update 2008. Washington, DC: Government of the District of Columbia. February 2009. Available at: http://dchealth.dc. gov/doh/lib/doh/pdf/ dc-hiv-aids-2008-updatereport.pdf. Accessed August 15, 2010.
31. Nguyen TQ, Gwynn RC, Kellerman SE, et al. Population prevalence of reported and unreported HIV and related behaviors among the household adult population in New York City, 2004. AIDS. 2008;22:281-287. doi: 10.1097/QAD.0b013e3282f2ef58.
32. Wiewel EW, Hanna DB, Begier EM, et al. High HIV prevalence and diagnosis rates in New York City black men. J Community Health. Published online ahead of print June 24, 2010. doi:10.1007/s10900-010-9291-0.
33. Branson BM, Handsfield HH, Lampe MA, et al. Revised recommendations for HIV testing of adults, adolescents, and pregnant women in health-care settings. MMWR Recomm Rep. 2006;55(RR14): 1-17. Available at: http://www.cdc.gov/mmwr/ preview/mmwrhtml/rr5514a1.htm. Accessed August 15, 2010.
34. Centers for Disease Control and Prevention. Persons tested for HIV-United States, 2006. MMWR Morb Mortal Wkly Rep. 2008;57:845-849. Available at: http://www.cdc.gov/mmwr/preview/mmwrhtml/mm5731a1.htm. Accessed August 15, 2010.
35. Beckwith CG, Flanigan TP, Del Rio C, et al. It is time to implement routine, not risk-based, HIV testing. Clin Infect Dis. 2005;40:1037-1040. doi:10.1086/428620.
36. Millett GA, Peterson JL. The known hidden epidemic HIV/AIDS among black men who have sex with men in the United States. Am J Prev Med. 2007;32(Suppl 1): S31-S33. doi:10.1016/j.amepre.2006.12.028.
37. EpiQuery: NYC Interactive Health Data System, Community Health Survey 2009. Database online. New York, NY: New York City Department of Health and Mental Hygiene. Available at: http://nyc.gov/health/epiquery. Accessed August 15, 2010.
38. Valdiserri RO, Holtgrave DR, West GR. Promoting early HIV diagnosis and entry into care. AIDS. 1999;13:2317-2330.
39. New York City Department of Hygiene and Mental Health. HIV Epidemiology and Field Services Semiannual Report. Vol 4, No 1. April 2009. Available at: http://www.nyc.gov/html/doh/downloads/pdf/dires/dires-2009-report-semi1.pdf. Accessed August 15, 2010.
40. Hanna DB, Pfeiffer MR, Torian LV, et al. Concurrent HIV/AIDS diagnosis increases the risk of short-term HIV-related death among persons newly diagnosed with AIDS, 2002-2005. AIDS Patient Care STDS. 2008;22:17-28. doi:10.1089/apc.2007.0042.
41. Marks G, Crepaz N, Senterfitt JW, et al. Meta-analysis of high-risk sexual behavior in persons aware and unaware they are infected with HIV in the United States: implications for HIV prevention programs. J Acquir Immune Defic Syndr. 2005;39:446-453.
42. Robbins GK, Spritzler JG, Chan ES, et al. Incomplete reconstitution of T cell subsets on combination antiretroviral therapy in the AIDS Clinical Trials Group Protocol 384. Clin Infect Dis. 2009;48:350-361. doi: 10.1086/595888.
43. Sterne JA, May M, Costagliola D, et al. Timing of initiation of antiretroviral therapy in AIDS-free HIV-1-infected patients: a collaborative analysis of 18 HIV cohort studies. Lancet. 2009;373:1352-1363. doi: 10.1016/S0140-6736 (09) 60612-7.
44. Torian LV, Wiewel EW, Liu KL, et al. Risk factors for delayed initiation of medical care after diagnosis of human immunodeficiency virus. Arch Intern Med. 2008;168:1181-1187. Available at: http://archinte.amaassn.org/cgi/content/ full/168/11/1181. Accessed August 15, 2010.
45. Gebo KA, Fleishman JA, Conviser R, et al. Racial and gender disparities in receipt of highly active antiretroviral therapy persist in a multistate sample of HIV patients in 2001. J Acquir Immune Defic Syndr. 2005;38:96-103. Available at: http://journals.lww.com/jaids/Fulltext/2005/01010/Racial-and- Gender-Disparities-in-Receipt-of-Highly.17.aspx. Accessed August 15, 2010.
46. Reif S, Whetten K, Thielman N. Association of race and gender with use of antiretroviral therapy among HIV-infected individuals in the southeastern United States. South Med J. 2007;100:775-781. doi: 10.1097/SMJ.0b013e3180f626b4.
47. Lucas GM, Griswold M, Gebo KA, et al. Illicit drug use and HIV-1 disease progression: a longitudinal study in the era of highly active antiretroviral therapy. Am J Epidemiol. 2006;163:412-420. doi:10.1093/aje/kwj059.
48. Strathdee SA, Stockman JK. Epidemiology of HIV among injecting and non-injecting drug users: current trends and implications for interventions. Curr HIV/AIDS Rep. 2010;7:99-106. doi:10.1007/s11904-010-0043-7.
49. Stall R. Efforts to prevent HIV infection that target people living with HIV/AIDS: what works? Clin Infect Dis. 2007;45(Suppl 4): S308-S312. doi:10.1086/522555.
50. Althoff KN, Gange SJ, Klein MB, et al. Late presentation for human immunodeficiency virus care in the United States and Canada. Clin Infect Dis. 2010;50:1512-1520. doi:10.1086/652650.
51. Althoff K, Gange S, Klein M, et al. Late presentation for HIV care in the US and Canada. Paper #982. Presented at: 17th Conference of Retroviruses and Opportunistic Infections (CROI); February 16-19, 2010; San Francisco, CA. Poster presentation available at: http://www.retroconference.org/2010/PDFs/982.pdf. Accessed August 15, 2010.
52. Mehta SH, Kirk GD, Astemborski J, et al. Temporal trends in highly active antiretroviral therapy initiation among injection drug users in Baltimore, Maryland, 1996-2008. Clin Infect Dis. 2010;50:1664-1671. doi:10.1086/652867.
53. Bogart LM, Kelly JA, Catz SL, et al. Impact of medical and nonmedical factors on physician decision making for HIV/AIDS antiretroviral treatment. J Acquir Immune Defic Syndr. 2000;23:396-404. Available at: http://journals.lww. com/jaids/Fulltext/2000/04150/Impact-of-Medical-and-Nonmedical-Factors-on. 6.aspx. Accessed August 15, 2010.
54. Crustinger-Perry B, Penner MC, Pund B, For the National Alliance of State and Territorial AIDS Directors (NASTAD). National ADAP Monitoring Project Annual Report. May 2010. Washington, DC: NASTAD; 2010. Available at: http://www.nastad.org/Docs/highlight/201053- 2010%20National%20ADAP%20Monitoring%20Report.pdf. Accessed August 15, 2010.
55. Sack K. Economy hurts government aid for H. I. V. drugs. The New York Times. June 30, 2010. Available at: http://www.nytimes.com/2010/07/01/us/ 01aidsdrugs.html?-r=1&scp=1&sq= Economy%20Hurts%20Government%20Aid%20for%20HIV%20Drugs&st=cse. Accessed August 15, 2010.
56. Mills EJ, Nachega JB, Buchan I, et al. Adherence to antiretroviral therapy in sub-Saharan Africa and North America: a meta-analysis. JAMA. 2006;296:679-690. Available at: http://jama.ama-assn.org/cgi/content/full/296/6/ 679. Accessed August 15, 2010.
57. Bangsberg DR. Preventing HIV antiretroviral resistance through better monitoring of treatment adherence. J Infect Dis. 2008;197(Suppl 3): S272-S278. doi:10.1086/533415.
58. Lazo M, Gange SJ, Wilson TE, et al. Patterns and predictors of changes in adherence to highly active antiretroviral therapy: longitudinal study of men and women. Clin Infect Dis. 2007;45:1377-1385. doi:10.1086/533415.
59. Levine AJ, Hinkin CH, Castellon SA, et al. Variations in patterns of highly active antiretroviral therapy (HAART) adherence. AIDS Behav. 2005;9:355-362. doi:10.1007/s10461-005-9009-y.
60. Bendavid E, Brandeau ML, Wood R, et al. Comparative effectiveness of HIV testing and treatment in highly endemic regions. Arch Intern Med. 2010;170:1347-1354. doi:10.1001/archinternmed.2010.249.
61. Fisher JD, Smith LR, Smith EM. Secondary prevention of HIV in the United States: past, current, and future perspectives. J Acquir Immune Defic Syndr. 2010;55(Suppl 2): S116-S121.
62. Vermund SH, Hodder SL, Justman JE, et al. Addressing research priorities for prevention of HIV infection in the United States. Clin Infect Dis. 2010;50(Suppl 3): S149-S155. doi:10.1086/651485.